Literature DB >> 22042321

Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?

Michael Drummond, Adrian Towse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22042321     DOI： 10.1007/s10198-011-0353-8

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  8 in total

Review 1.  Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.

Authors:  Joel Lexchin; Paul Grootendorst
Journal:  Int J Health Serv       Date:  2004       Impact factor: 1.663

2.  The impact of user charges on the consumption of drugs. Empirical evidence and economic implications.

Authors:  U G Gerdtham; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

Review 3.  The effects of prescription drug cost sharing: a review of the evidence.

Authors:  Teresa B Gibson; Ronald J Ozminkowski; Ron Z Goetzel
Journal:  Am J Manag Care       Date:  2005-11       Impact factor: 2.229

Review 4.  Value-based insurance design.

Authors:  Michael E Chernew; Allison B Rosen; A Mark Fendrick
Journal:  Health Aff (Millwood)       Date:  2007-01-30       Impact factor: 6.301

5.  Moral hazard in insurance, value-based cost sharing, and the benefits of blissful ignorance.

Authors:  Mark V Pauly; Fredric E Blavin
Journal:  J Health Econ       Date:  2008-07-18       Impact factor: 3.883

6.  Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?

Authors:  Andreas Gerber; Stephanie Stock; Charalabos-Markos Dintsios
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

7.  Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries.

Authors:  Patricia M Danzon; Adrian Towse; Andrew W Mulcahy
Journal:  Health Aff (Millwood)       Date:  2011-08       Impact factor: 6.301

8.  Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.

Authors:  Michael Drummond; Bengt Jönsson; Frans Rutten; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2010-08-28
  8 in total
  10 in total

1.  Is the US "leading from behind" on health policy?

Authors:  Peter J Neumann; Cayla J Saret
Journal:  Eur J Health Econ       Date:  2013-12-10

2.  Could co-payments on drugs help to make EU health care systems less open to political influence?

Authors:  Livio Garattini; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2013-10

3.  Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.

Authors:  Mahdi Gharaibeh; Ali McBride; David S Alberts; Brian Erstad; Marion Slack; Nimer Alsaid; J Lyle Bootman; Ivo Abraham
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

Review 4.  Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

Authors:  Fabrice Smieliauskas; Chun-Ru Chien; Chan Shen; Daniel M Geynisman; Ya-Chen Tina Shih
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

Review 5.  A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Authors:  Lianne Barnieh; Fiona Clement; Anthony Harris; Marja Blom; Cam Donaldson; Scott Klarenbach; Don Husereau; Diane Lorenzetti; Braden Manns
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

6.  The impact of copayments on mental healthcare utilization: a natural experiment.

Authors:  Timo R Lambregts; René C J A van Vliet
Journal:  Eur J Health Econ       Date:  2017-08-03

7.  Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy.

Authors:  Jacopo Lenzi; Maria Michela Gianino
Journal:  BMJ Open       Date:  2022-03-08       Impact factor: 2.692

8.  Can European Countries Improve Sustainability of Health Care Financing through Patient Cost-Sharing?

Authors:  Marzena Tambor; Milena Pavlova; Stanisława Golinowska; Wim Groot
Journal:  Front Public Health       Date:  2015-08-12

9.  Impact of financial burden, resulting from prescription co-payments, on antihypertensive medication adherence in an older publically insured population.

Authors:  Paul Dillon; Susan M Smith; Paul Gallagher; Gráinne Cousins
Journal:  BMC Public Health       Date:  2018-11-20       Impact factor: 3.295

10.  Financial Catastrophism Inherent with Out-of-Pocket Payments in Long Term Care for Households: A Latent Impoverishment.

Authors:  Raúl Del Pozo-Rubio; Isabel Pardo-García; Francisco Escribano-Sotos
Journal:  Int J Environ Res Public Health       Date:  2020-01-01       Impact factor: 3.390
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.